1	The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing
2	on neutralization breadth against SARS-CoV-2 variants of concern
3	
4	Carl Graham ^{1*} , Thomas Lechmere ^{1*} , Aisha Rehman ¹ , Jeffrey Seow ¹ , Ashwini Kurshan ¹ ,
5	Isabella Huettner ¹ , Thomas J.A. Maguire ¹ , Jerry Tam ¹ , Daniel Cox ¹ , Christopher Ward ¹ ,
6	Mariusz Racz ² , Anele Waters ² , Christine Mant ³ , Michael H. Malim ¹ , Julie Fox ¹ , Katie J.
7	Doores ¹ #
8	
9	¹ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's
10	College London, London, UK.
11	² Harrison Wing, Guys and St Thomas' NHS Trust, London, UK.
12	³ Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology
13	and Microbial Sciences, King's College London, London, UK.
14	
15	* These authors contributed equally
16	# Corresponding author: <u>katie.doores@kcl.ac.uk</u>
17	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract:

20 COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As 21 SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to 22 emerge, there is increased need to identify immunogens and vaccination regimens that 23 provide the broadest and most durable immune responses. We compared the magnitude and 24 breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B 25 cells, in individuals receiving a second dose of BNT126b2 at a short (3-4 week) or extended 26 interval (8-12 weeks) and following a third vaccination approximately 6-8 months later. We 27 show that whilst an extended interval between the first two vaccinations can greatly increase 28 the breadth of the immune response and generate a higher proportion of Spike reactive 29 memory B cells, a third vaccination leads to similar levels between the two groups. 30 Furthermore, we show that the third vaccine dose enhances neutralization activity against 31 omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following 32 breakthrough infection during the UK omicron wave. These findings are relevant for 33 vaccination strategies in populations where COVID-19 vaccine coverage remains low.

34 Introduction:

35 Development of vaccines against SARS-CoV-2 has been a vital step in controlling the 36 global COVID-19 pandemic. Most approved vaccines use the SARS-CoV-2 Spike antigen to elicit a neutralizing antibody response as well as generating cell-mediated immunity. The 37 38 Spike glycoprotein interacts with the angiotensin-converting enzyme 2 (ACE2) on host cells and facilitates viral entry. One of the greatest challenges faced by current vaccines has been 39 40 the emergence of SARS-CoV-2 viral variants of concern (VOCs) that encode mutations in the 41 Spike protein, including alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2) and omicron (sub-42 lineage members BA.1, BA.2, BA.4 and BA.5). Numerous studies have shown that these 43 Spike mutations can lead to partial escape in convalescent and vaccinee sera, with the 44 greatest reduction in neutralization being observed for omicron sub-lineages [1-5]. Therefore, 45 immunogens and immunization regimes that elicit durable neutralizing antibody (nAb) 46 responses with broad activity against both known and newly emerging variants is highly 47 desirable.

48 In December 2020, the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine was 49 given approval for use in the UK. The approved regimen was two doses administered at a 3-50 4-week interval, but in January 2021 a change to UK policy meant that the BNT162b2 booster 51 vaccination was administered with an extended interval of 8-12 weeks. The rationale behind 52 this change was to provide as much of the UK population with some level of immunity in the 53 face of a large wave of SARS-CoV-2 alpha variant infections [6]. Initially, most COVID-19 vaccines required two vaccinations to provide efficacy against the Wuhan (wild-type, WT) 54 55 alpha and delta VOCs. However, due to waning of vaccine-elicited nAb levels [7] and with the 56 emergence of omicron/BA.1, which encodes >30 mutations in Spike, a third vaccination (either BNT162b2 or mRNA-1273) became recommended. A third vaccine has been shown to 57 58 increase neutralization titres against omicron/BA.1 [3-5, 8] and to restore vaccine efficacy 59 against omicron/BA.1 [9-11] however, breakthrough infections (BTI) in vaccinated individuals have been observed at increased frequencies compared to previous dominant variants [9-11]. 60

We sought to determine how the interval between the 1st and 2nd BNT162b2 61 62 vaccinations impacted on neutralization breadth and potency against current and newly 63 emerging VOCs in the short-term (post 2-doses) and in the long-term (post 3-doses), and how subsequent BTI during the UK omicron wave (January to February 2022) affected 64 65 neutralization of newer omicron sub-lineage members. We show that broader plasma neutralizing activity is observed when the 2nd dose is given with extended 8–12 week interval 66 (extended group) compared to those receiving the 2nd dose with a 3-4 week interval (short 67 68 group). However, the advantage of the extended booster to neutralization is not displayed following a 3rd vaccination where robust neutralization of omicron lineages members (BA.1. 69 70 BA.2, BA.4 and BA.5) is observed in both groups. Finally, we show that omicron BTI further 71 boosts the neutralization activity against omicron sub-lineages. Overall, this research provides 72 insights into optimizing vaccine regimens to provide the greatest neutralization breadth.

73

74 Results

75 Vaccine cohort description.

76 Plasma and PBMCs were collected from individuals receiving the BNT162b2 vaccine 77 either with a short booster interval (3-4 weeks, n = 19, short-group) or an extended booster 78 interval (8-12 weeks, n = 28, extended-group) (Figure 1A). For the extended-group blood was collected prior to vaccination (visit 1), 3 weeks post 1st dose (visit 2) and post 2nd dose (visit 79 80 3). For the short-group, blood was only collected post 2nd dose (visit 3). Blood was also collected from both groups 6 months post 2nd vaccine dose (visit 4) and further samples was 81 taken 3-4 weeks and 6-months post 3rd vaccine (visit 5 and visit 6, respectively). For individuals 82 experiencing a BTI, blood was also collected post infection (visit 7). 83

The short-group was 84.2% female, with an average age of 44.1 years (interquartile range, 15.0 years) whereas the extended-group was 53.6% female, with a slightly lower average age of 38.0 years (interquartile range, 14.7 years) (**Figure 1B&C**). Information on previous SARS-CoV-2 infection was recorded at each blood draw and the presence of IgG to Nucleoprotein (N) was measured to determine previous asymptomatic SARS-CoV-2

infections or infections occurring prior to community PCR testing. Previous infection was detected in 3/19 from the short-group and in 10/28 from the extended-group (**Figure 1D**). The average interval between vaccine doses was 25.2 days (interquartile range, 3.5 days) for the short group and 71.0 days (interquartile range, 11.3 days) in the extended group (**Figure 1E**).

94 Anti-Spike IgG levels are similar in short and extended booster groups.

95 IgG binding to recombinant Wuhan-1 Spike was measured by ELISA and the half-96 maximal binding (ED₅₀) calculated (**Figure 2**). As reported previously [12-16], individuals who 97 had experienced a SARS-CoV-2 infection prior to vaccination had higher Spike IgG levels 98 compared to naïve individuals after the 1st vaccine dose (visit 2) (**Figure 2B**). However, similar 99 levels of anti-Spike IgG were observed in the SARS-CoV-2 naïve and convalescent donors 100 following the 2nd vaccination (visit 3) (**Figures 2A** and **2B**).

For SARS-CoV-2 naïve individuals, comparison of ED_{50} between the short and extended groups showed no statistical differences at visit 3, although there was a trend towards higher levels in the extended group (**Figure 2C**). Both groups showed waning of the anti-Spike IgG levels 6 months post 2nd vaccine (visit 4) which were subsequently boosted after participants received a 3rd vaccine dose (visit 5) (**Figures 2A and 2B**).

106

Previous SARS-CoV-2 infection leads to higher nAb titres following the first vaccine dose.

109 Next, plasma neutralization breadth and potency were determined using HIV-1 110 lentiviral particles pseudotyped with either the SARS-CoV-2 Spike of Wuhan-1 (vaccine 111 strain), alpha, delta, beta or omicron/BA.1 VOCs and a HeLa cell line stably expressing ACE2 112 as the target cell [17]. Analysis of neutralizing responses after a single vaccine dose (visit 2) 113 was only conducted on the extended-group due to sample availability (**Figure 1A**). Consistent 114 with previous studies [12-16], following 1-dose of BNT162b2, geometric mean titres (GMTs) 115 against the matched vaccine strain (Wuhan-1, wildtype, WT) were higher is those who had a

116 SARS-CoV-2 infection prior to vaccination (**Figures 3A-3C**). Furthermore, previously infected

individuals showed greater neutralization breadth against VOCs (Figure 3A-3C).

118

119 An extended interval between the 2nd vaccine dose enhances the breadth of the 120 neutralizing antibody response.

121 Following two doses of BNT162b2 in SARS-CoV-2 naïve individuals, GMTs against 122 the matched vaccine strain (Wuhan-1, WT) were similar between the short and extended 123 booster groups (Figure 3D-3F). In both the short and extended-groups, higher GMTs were 124 observed for individuals that had a SARS-CoV-2 infection prior to vaccination (Figure 3G-3I) 125 [12-16]. In SARS-CoV-2 naïve individuals (Figures 3D and 3E), the broadest neutralization 126 activity against VOCs was observed in the extended booster group where a modest 1.1–1.4-127 fold reduction in neutralization was observed against alpha, delta, mu and beta and a 3.6-fold 128 reduction against omicron/BA.1 (Figure 3E). For those in the short-group, a larger reduction 129 in neutralization potency against VOCs was observed, with greater reductions against beta 130 (6.1-fold) and omicron (14.2-fold) (Figure 3D). Comparison between GMTs of the short and 131 extended booster groups showed a significantly reduced potency against mu, beta and 132 omicron/BA.1 VOCs in the short booster group (Figure 3F). Although overall GMTs against VOCs were higher in previously infected vaccinees (Figure 3G-3I), the extended booster 133 134 group also showed higher GMTs against beta and omicron/BA.1 than the short booster group. However, this difference did not reach significance due to the small sample size (Figure 3I). 135

To determine whether the extended booster generated neutralization breadth beyond
SARS-CoV-2 VOCs, neutralization was also measured against SARS-CoV-1 which shares
73% sequence [18] similarity with Spike of SARS-CoV-2. Although neutralization titres were
generally low, individuals receiving the extended booster showed low levels of SARS-CoV-1
neutralization (Figure 3J) with a GMT that was higher than in the short-group.

141

142 An extended vaccine interval enhances the magnitude of the memory B cell response

143 To further examine how vaccine interval impacts on the B cell response, we next 144 measured the frequencies of Spike-reactive memory B cells in the short and extended booster 145 groups using flow cytometry (Figure 4A-B and Figure S1A) [12, 19]. The frequency of Wuhan-1 Spike-reactive memory B cells was measured in pre-vaccination samples (visit 1) for the 146 147 extended booster group only (due to sample availability) and in both groups following the 2nd vaccination (visit 3). Overall, where paired samples were available, the overall frequency of 148 149 memory B cells did not change over the course of the analysis (Figure S1B). Participants who 150 had a SARS-CoV-2 infection prior to vaccination had a distinct population of Spike reactive 151 memory B cells in the pre-vaccine sample (mean 0.20 %, range 0.10 - 0.34%) compared to 152 naïve individuals (mean 0.02 %, range 0.01 - 0.06%) (Figure 4C). Following two vaccine 153 doses, the percentage of Spike-reactive memory B cells increased independent of prior 154 SARS-CoV-2 exposure (Figure 4C).

In SARS-CoV-2 naïve participants, a higher frequency of Spike reactive memory B cells was observed in the extended booster group (mean 0.52 %, range 0.20 - 2.36%) compared to the short booster group (mean 0.19 %, range 0.07 - 0.38%) after the 2nd vaccine dose (**Figure 4C**). When considering the frequency of Spike-reactive B cells in previously infected vaccinated donors, the percentage (mean 0.67 %, range 0.24 - 1.71 %) was similar to SARS-CoV-2 naïve individuals in the extended group.

161 The isotype of the Spike-reactive memory B cells was considered further (Figure 4D). 162 In samples collected from previously infected individuals prior to vaccination, an average 64.5% of the Spike-reactive memory B cells were IgG positive (Figure 4D) and the average 163 164 percentage increased upon vaccination to 81.8% (Figure 4D) suggesting an improvement in 165 the quality of the response. In COVID-19 naïve individuals, a higher percentage of IgG+ Spikereactive memory B cells was seen in the extended-booster group (86.5%) compared to the 166 167 short-booster group (74.5%). A positive correlation between the percentage of Spike-reactive 168 memory B cells and the ED_{50} and ID_{50} (Figures 4E and 4F) was observed after two vaccine 169 doses independent of booster interval or previous SARS-CoV-2 exposure.

Overall, an extended period between the first and second vaccine dose increases themagnitude of the Spike-specific B cell response.

172

173 Neutralizing antibody levels decline at 6 months but are boosted and neutralization

174 broadened by a third vaccine dose.

To understand the durability of the nAb response following two vaccine doses, neutralization titres were measured 6 months post second vaccine dose (visit 4). Plasma neutralization activity against all VOCs (WT, alpha, delta, beta and omicron (BA.1)) had declined in both groups (**Figure 5A-D**) as reported in other recent studies [4, 8, 20]. Although the neutralization of the most antigenically distant VOCs (beta and omicron/BA.1) had declined, titres remained higher in the extended booster group compared to the short booster group (**Figure 5A** and **5B**).

182 In September 2021, a vaccine booster programme was initiated in the UK and blood was collected from individuals 3-weeks after receiving a 3rd vaccine dose (visit 5). The impact 183 184 on IgG levels to Spike and neutralization breadth and potency was measured. The third 185 vaccine dose (visit 5) increased Spike IgG binding (Figure 2) and the plasma neutralizing 186 activity (Figure 5A-D) compared to visit 4 in both groups. Whereas after the second dose 187 there had been a clear distinction in neutralization breadth between the short and extended 188 booster groups, following administration of a third vaccine dose the neutralizing titres against WT, alpha, delta, beta and omicron/BA.1 were very similar (Figure 5A-D). Importantly, a 3rd 189 vaccination with ancestral SARS-CoV-2 spike increased neutralization breadth against the 190 191 most highly diverse beta and omicron/BA.1 variants (Figure 5C). Overall, the reduced 192 neutralization breadth observed in the short booster group after two vaccine doses is rescued following a third vaccine dose. 193

194

195 Broader neutralization is associated with have higher avidity against Spike.

Antibody binding avidity has been associated with antibody maturation [21-25]. To determine whether enhanced neutralization breadth was related to higher avidity of antibody

198 binding in the extended booster group we next measured an avidity index for samples 199 collected 3-weeks and 6 months after the second vaccine dose (visit 3 and 4) and 3-weeks 200 after the third vaccine dose (visit 5). The avidity was measured by comparing the area under the curve in ELISA, with and without an 8M Urea washing step. For SARS-CoV-2 naïve 201 202 individuals at visit 3, the extended booster group had a significantly higher avidity index than the short booster group (Figure 5E). However, this difference was reduced in when comparing 203 previously infected individuals. The avidity index 6 months post 2nd vaccine (visit 4) was largely 204 unchanged (**Figure 5F**). Following the 3rd vaccination (visit 5) where neutralization breadth 205 206 was similar across the two groups, the avidity index increased in both groups and the 207 difference in avidity index between the short and extended groups was no longer significant (Figure 5G). The avidity index 3-weeks after 2nd vaccine dose (visit 3) was correlated with the 208 209 ID₅₀ against each VOC (Figure 5I). No significant correlation was observed for WT. However, 210 the correlation coefficient was greatest for beta and omicron/BA.1 which are most antigenically 211 distant to the vaccine strain and suggests that avidity may be a good indicator VOC cross-212 reactivity. The avidity index also correlated with the % of Spike-reactive memory B cells 213 (Figure 5H).

214

215 Neutralization of BA.2 and BA.4/5 sub-lineages.

216 Since omicron/BA.1 became the dominant global variant worldwide, several related SARS-CoV-2 omicron sub-lineages have been reported that encode unique amino acid 217 changes in Spike. BA.2 has driven a recent wave in the UK and encodes 21 identical mutations 218 219 to BA.1 (including K417N, N440K and E484A) and 8 additional mutations across NTD and 220 RBD. BA.4 and BA.5, which encode identical Spikes proteins, are thought to be driving a 5th 221 wave in South Africa [26]. The BA.4/BA.5 Spike is similar to BA.2 but has additional mutations 222 delta69-70, L452R and F486V and lacks the Q493R mutation. Emergence of these highly 223 transmissible sub-lineages has led to an increased rate of breakthrough infections (BTIs) and, 224 within the cohort described here, fourteen participants experienced BTI between mid-225 December 2021-March 2022. In mid-December BA.1 made up >80% of UK infections and the

BA.1 and BA.2 sub-lineages made up 95% of infections from mid-January [27]. Therefore,
BTIs in participants were presumed to be caused by BA.1 or BA.2 VOCs (visit 7). Blood was
also collected from six participants 6 months post 3rd dose (visit 6).

To assess susceptibility to the recently reported BA.4/BA.5 variants and to determine 229 230 the impact of BA.1/BA.2 BTI on the antibody response, we measured neutralization against D614G, BA.1, BA.2 and BA.4/BA.5 following three BNT162b2 doses (at 3-weeks (visit 5) and 231 232 6-months (visit 6) post boost) and in those who subsequently experienced a BTI (3-weeks 233 post infection (visit 7)) (Figure 6). Due to the smaller number of samples available, all plasma were considered together for analysis. For plasma collected 3-weeks post 3rd vaccine dose 234 235 (visit 5), good neutralization against BA.1, BA.2 and BA.4/5 was detected but GMTs were 236 slightly decreased compared to D614G, with the greatest reduction being 2.2-fold against BA.4/5 (Figure 6A). Six months post 3rd vaccine dose (visit 6), neutralization titres had 237 decreased against all variants (Figure 6B and 6D) as seen six months post 2nd vaccine dose 238 239 (Figure 5). However, in those who experienced a BA.1/BA.2 BTI (visit 7) neutralization titres 240 increased against all variants compared to visit 5 and robust cross-neutralization of all omicron 241 sub-lineages was detected (Figure 6C and 6E). The largest fold increase in GMT following 242 BTI was observed against BA.1 and BA.2 (Figure 6E).

Overall, a third vaccine dose generates neutralization against omicron sub-lineages
BA.1, BA.2 and BA.4/5 which is further enhanced by BA.1/BA.2 BTI.

245

246 Discussion

Elicitation of nAbs with broad activity against both known and newly emerging variants is highly desirable and vital in controlling the current COVID-19 pandemic. Here we studied the impact of vaccine interval on the breadth and potency of the SARS-CoV-2 neutralizing antibody response. We showed that an extended interval between the 1st and 2nd dose of the BNT162b2 vaccine enhances neutralization breadth initially. However, a third vaccine dose generated a robust and broad neutralizing response against VOCs independent of the interval between 1st and 2nd vaccine doses. It has been extensively reported that 'hybrid' immunity,

immunity derived from SARS-CoV-2 infection followed by vaccination, leads to superior
neutralization following 1-dose of COVID-19 vaccine [12-16]. Our results showing higher
antibody binding and neutralization in previously infected individuals receiving one BNT162b2
dose are consistent with these reports.

258 Here, we show than an extended interval between the 1st and 2nd vaccine dose enhances the immune response in four ways. Firstly, and similar to previous reports, there is 259 260 an increase in IgG binding (ED₅₀) to Spike in the extended booster group following the 2nd 261 immunization [23, 28, 29] and secondly, the Spike-reactive IgG bind with higher avidity [23]. 262 Thirdly, broader neutralizing activity against VOCs (including BA.1) is generated [30, 31]. 263 Finally, a higher percentage of Spike-reactive IgG⁺ memory B cells is detected in SARS-CoV-264 2 naïve individuals receiving an extended booster. Binding avidity correlated most strongly 265 with the ID₅₀ against the most antigenically distinct VOCs. The higher binding avidity in the 266 extended group suggests that antibodies have undergone higher levels of antibody maturation 267 [21-24]. Indeed, wider SARS-CoV-2 neutralization breadth has been associated with 268 increased somatic hypermutation [12, 32-34]. We have recently reported that mAbs isolated 269 from an individual receiving 2-doses of the ChadOx1 AZD1222 vaccine at a 12-week interval 270 were more highly mutated than those isolated from SARS-CoV-2 convalescent donors and 271 displayed greater neutralization breadth [32]. Several studies have shown that mRNA 272 vaccination leads to a robust memory B cell response and induces persistent germinal centre 273 reactions that continue for months after primary vaccination [12, 19, 35, 36]. Therefore, a longer interval between the 1st and 2nd vaccine dose would allow extended germinal centre 274 275 reactions to take place, leading to increased levels of somatic hypermutation and higher 276 affinity to vaccine antigen.

277 Neutralization titres decreased 6 months post 2nd vaccine dose [20]. However, 278 consistent with previous research, we show that titres are boosted following the 3rd BNT162b2 279 vaccination. Importantly, neutralization breadth increased against beta and omicron sub-280 lineages independent of the interval between the 1st and 2nd vaccine doses leading to overall 281 similar levels of cross-neutralizing activity in both the short and extended booster groups. This

increase in neutralization breadth was accompanied by an increase in the Spike-reactive IgG
binding avidity in the short booster group, indicative of continued affinity maturation.
Nussenzweig and co-workers identified antibody lineages that had undergone further somatic
hypermutation following a 3rd dose of COVID-19 mRNA vaccine and these mAbs had superior
neutralization breadth and potency [37]. Relevant to the COVID-19 pandemic at the time of
writing (June 2022), neutralization against the antigenically distant VOCs BA.1 [3-5, 8], BA.2
[2, 38, 39] and BA.4/BA.5 [40-42] also increased following a 3rd vaccine dose in both groups.

289 Following BTI during the UK BA.1 or BA.2 wave, neutralization titres against D614G, 290 BA.1, BA.2 and BA.4/BA.5 increased in this cohort independent of previous SARS-CoV-2 291 infection. The fold increases in GMT were larger against Omicron sub-lineages compared to 292 against D614G. Increases in omicron sub-lineage neutralization following omicron BTI has 293 been observed in other cohorts [43-45]. Furthermore, boosting mRNA vaccinated mice with 294 an omicron/BA.1 based mRNA vaccine increased serum neutralization activity and protection 295 against omicron/BA.1 [46]. Recent studies indicate that the increase in cross-neutralizing 296 activity is mostly driven by re-activation of B cell clones initially generated through vaccination 297 with Wuhan-1 Spike that cross-react with the VOC, with little evidence of the generation of a 298 de novo VOC-specific antibody response [44, 47, 48]. These observations are contradictory 299 to recent reports suggesting that antibody responses to omicron/BA.1 were limited following 300 an omicron BTI in triple vaccinated donors who had been infected prior to vaccination [49].

301 The findings of this study are applicable in populations where COVID-19 vaccine coverage remains low and where there is limited vaccine supply. In vaccine naïve populations, 302 303 an extended interval will likely be beneficial through generation of broader antibody-based 304 immunity against VOCs in the first six months following the 2nd vaccine dose. Indeed, vaccine effectiveness was shown to be significantly higher in those receiving a longer interval between 305 mRNA doses [50, 51]. However, whilst there is broader activity following the 2nd vaccine dose 306 in the extended group, there would be a longer period following the 1st vaccine in which 307 antibody titres will remain low and narrow which in turn may lead to a higher risk of infection 308 309 during this period. Importantly, despite the interval between the 1st and 2nd vaccine doses, a

third vaccine dose increases neutralization against the current VOCs including omicron sub-lineages BA.1, BA.2, BA.4 and BA.5.

In summary, in a SARS-CoV-2 naïve population, an extended interval between the 1st and 2nd doses of BNT162b2 leads to an increased neutralization breadth, Spike binding avidity and frequency of Spike-reactive memory B cells. However, this advantage is lost when a 3rd vaccine dose is administered 6-8 months later where broad neutralization against current omicron sub-lineages is observed in both groups. These findings provide insights into optimizing vaccine regimens to provide the greatest neutralization breadth.

318

319 Limitations of the study

A limitation of this study is the relatively small sample size in each group which limits the power of the statistical analysis. The impact on cell-mediated immune responses has not been investigated. However, Hall *et al* have previously show that no significant differences in Spike-specific polyfunctional CD4+ T cell responses between the short and extended groups [52] whereas Payne et al reported higher levels of these cells in the extended group [28]. This study does not assess whether the broader neutralization response in the extended-group reduced breakthrough infections.

327

328 Materials and Methods:

329

Ethics. This study used human samples collected with written consent as part of a study entitled "Antibody responses following COVID-19 vaccination". Ethical approval was obtained from the King's College London Infectious Diseases Biobank (IBD) (KDJF-110121) under the terms of the IDB's ethics permission (REC reference: 19/SC/0232) granted by the South Central – Hampshire B Research Ethics Committee in 2019.

335

336 **Protein expression and purification.**

Recombinant Spike and nucleoprotein for ELISA were expressed and purified aspreviously described [17, 53].

339

340 ELISA (Spike and nucleoprotein).

341 96-well plates (Corning, 3690) were coated with antigen at 3 µg/mL overnight at 4°C. The plates were washed (5 times with PBS/0.05% Tween-20, PBS-T), blocked with blocking 342 343 buffer (5% skimmed milk in PBS-T) for 1 h at room temperature. Serial dilutions of plasma in 344 blocking buffer were added and incubated for 2 hr at room temperature. Plates were washed 345 (5 times with PBS-T) and secondary antibody was added and incubated for 1 hr at room 346 temperature. IgG was detected using Goat-anti-human-Fc-AP (alkaline phosphatase) 347 (1:1,000) (Jackson: 109-055-098). Plates were washed (5 times with PBS-T) and developed 348 with AP substrate (Sigma) and read at 405 nm.

349

350 Avidity ELISA

The ELISA was carried out as described above. A 4-point titration (starting at 1:25, 1:4 dilution series) was used. After incubation of plasma, one half of the plate was incubated with 8M Urea and the other half incubated with PBS for 10mins before washing 5-time with PBS-T. The area under the curve was determined in Prism (Log dilution). The avidity index was calculated using the following formula:

356

357

$Avidity \ index = 100 * \left(\frac{Area \ under \ curve \ with \ 8M \ Urea}{Area \ under \ curve \ with \ no \ Urea}\right)$

358 Neutralisation assay with SARS-CoV-2 pseudotyped virus

Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wuhan-1, D614G, alpha (B.1.1.7), beta (B.1.351), delta (B.1.671.2), mu (B.1.621), omicron (BA.1, BA.2 or BA.4/5) were prepared as previously described [17, 54]. Viral particles were produced in a 10 cm dish seeded the day prior with 5x10⁶ HEK293T/17 cells in 10 ml of complete Dulbecco's Modified Eagle's Medium (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol)

foetal bovine serum (FBS), 100 IU/ml penicillin and 100 μ g/ml streptomycin. Cells were transfected using 90 μ g of PEI-Max (1 mg/mL, Polysciences) with: 15 μ g of HIV-luciferase plasmid, 10 μ g of HIV 8.91 gag/pol plasmid and 5 μ g of SARS-CoV-2 spike protein plasmid [55, 56]. The supernatant was harvested 72 hours post-transfection. Pseudotyped virus particles was filtered through a 0.45 μ m filter, and stored at -80°C until required.

Serial dilutions of plasma samples (heat inactivated at 56°C for 30mins) were prepared with 369 370 DMEM media (25µL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped virus 371 (25µL) for 1-hour at 37°C in half-area 96-well plates. Next, Hela cells stably expressing the 372 ACE2 receptor were added (10,000 cells/25µL per well) and the plates were left for 72 hours. 373 Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using 374 a Victor™ X3 multilabel reader (Perkin Elmer). Each serum sample was run in duplicate and 375 was measured against the five SARS-CoV-2 variants within the same experiment using the 376 same dilution series.

377 FACS analysis of Spike-specific memory B cells.

378 Flow cytometry of cryopreserved PBMCs was performed on a BD FACS Melody as previously 379 described. SARS-CoV-2 Wuhan-1 Spike was pre-complexed with the streptavidin fluorophore (Alexa-488) at a 4:1 molar ratio prior to addition to cells. PBMCs were incubated with Fc block 380 for 15 minutes at 4°C. PBMCs were stained with anti-CD3-BV510 (Biolegend), anti-CD19-381 382 PerCP-Cy5.5 (Biolegend), anti-IgD-Pacific Blue (Biolegend), anti-CD27-BV785 (Biolegend), anti-CD38-APC-Cy7 (Biolegend), anti-CD20-APC (Biolegend), anti-IgG-PE-Cy7 (BD 383 384 Biosciences), anti-IgM-PE (Biolegend) and Spike-Alexa Fluor 488 for 1 hour at 4°C. PBMCs 385 were washed with PBS and stained with live/dead for 1 hour at 4°C.

386

388 Figures and legends:

389

Figure 1: A) Vaccination and blood sampling schedule in short and extended vaccine groups.
Horizontal line shows the mean age for each group. B) Difference in age between short- and
extended-groups. C) Gender of participants in each group. D) Frequency of previous SARSCoV-2 infection. E) Length of time between the 1st and 2nd dose of BNT162b2 vaccine.
Horizontal line shows the mean days between vaccine doses. Short- and extended-groups
shown in circle and triangles, respectively.



397

398 Figure 2: IgG binding titres to SARS-CoV-2 Spike over time. A) Comparison of geometric 399 mean ED₅₀ values between SARS-CoV-2 naïve individuals (open black circle) and those 400 previously infected before vaccination (grey/red circles) in short-booster group. B) 401 Comparison of geometric mean ED₅₀ values between SARS-CoV-2 naïve individuals (open 402 black triangle) and those previously infected before vaccination (grey/red triangle) in 403 extended-booster group. C) Comparison of geometric mean ED₅₀ values between short- and 404 extended-booster groups at visit 3, 4 and 5. Dotted line represents the lowest limit of detection 405 for the assay. D'Agostino and Pearson tests were performed to determine normality. Based 406 on this result, multiple Mann-Whitney tests or unpaired t tests using a two-stage linear step-407 up procedure of Benjamini, Krieger and Yekutieli were employed to determine significance between groups. ns P > 0.05, * P \leq 0.05, ** P \leq 0.01, *** P \leq 0.001 and **** P \leq 0.0001. 408



409

410

412 Figure 3: Neutralization breadth and potency following two-doses of BNT162b2.

Neutralization was measured against wuhan-1 (WT), alpha, delta, mu, beta and omicron/BA.1. 413 414 A) Neutralization following a single BNT162b2 vaccine dose (visit 2) in naïve individuals (n = 18). B) Neutralization following a single BNT162b2 vaccine dose in individuals infected with 415 416 SARS-CoV-2 prior to vaccination (n = 10). Data from individual donors are linked and fold changes compared to WT shown above. C) GMT comparison between SARS-CoV-2 naïve 417 individuals (open triangle) and convalescent donors (grey triangle) following one vaccine dose. 418 419 The horizontal line shows the GMT. Neutralization data following 2-vaccine doses (visit 3) in 420 SARS-CoV-2 naïve individuals in **D**) the short booster group (n = 16), and **E**) the extended 421 booster group (n = 18). Data from individual donors are linked and fold changes compared to 422 WT shown above. F) GMT comparison in SARS-CoV-2 naïve individuals receiving the short 423 booster interval (open circle) and extended booster (open triangle). The horizontal line shows 424 the GMT. Neutralization data following 2-vaccine doses (visit 3) in SARS-CoV-2 convalescent 425 individuals in **G**) the short booster group (n = 3) and **H**) the extended booster group (n = 9). 426 Data from individual donors are linked and fold changes compared to WT shown above. I) 427 GMT comparison in SARS-CoV-2 convalescent individuals receiving the short booster interval 428 (grey circle) and extended booster (grey triangle). The horizontal line shows the GMT. J) 429 Neutralization of SARS-CoV-1. The horizontal dotted line is the lowest limit of detection. 430 D'Agostino and Pearson tests were performed to determine normality. Based on this result, multiple Mann-Whitney tests using a two-stage linear step-up procedure of Benjamini, Krieger 431 and Yekutieli were employed to determine significance between groups. ns P > 0.05, * P ≤ 432 433 0.05, ** P ≤ 0.01 , *** P ≤ 0.001 and **** P ≤ 0.0001 .

с

10000

100

10

wт

Alpha Delta Mu

VOC















Visit 2

Г

△ COVID-

▲ COVID+

....

ŝ

÷

Beta Omicron

i SARS-CoV-1 10000 1000 ID:0(log) 10 10 Exented COVID* Short COND*

435 436

438 Figure 4. Higher percentage of SARS-CoV-2 Spike-reactive memory B cells are detected 439 in the extended booster group. Percentage of Spike-reactive memory B cells were 440 determined by flow cytometry. A) Example pre-bleed (visit 1) PBMC staining for SARS-CoV-2 naïve individual. B) Example visit 3 PBMC staining for SARS-CoV-2 naïve individual. 441 442 Example of full flow analysis shown if Figure S1A. C) Percentage Spike-reactive memory B cells at visit 1 and visit 3 were determined by flow cytometry. Previously infected individuals 443 shown in red/grey. Extended and short interval groups shown with triangle and circle symbols, 444 445 respectively. D'Agostino and Pearson tests were performed to determine normality. Based on 446 this result, differences between groups were assessed using a Brown-Forsythe ANOVA test with Dunnett's T3 multiple comparisons post hoc. ns P > 0.05, * P \leq 0.05, ** P \leq 0.01, *** P \leq 447 0.001 and **** $P \le 0.0001$. **D)** Percentage of IgG, IgM or other Spike-reactive memory B cells 448 449 for each vaccine group. E) Correlation between Spike $IgG ED_{50}$ and percentage of Spike-450 reactive memory B cells. F) Correlation between ID₅₀ against Wuhan-1 pseudotyped virus and 451 percentage of Spike-reactive memory B cells. (Spearman's correlation, r; a linear regression 452 was used to calculate the goodness of fit, r^2).





457 Figure 5. Neutralization potency decreases 6-months post 2nd vaccine but breadth and

458 potency increase after a 3rd vaccine dose. Neutralization ID₅₀ against WT, alpha, delta, beta 459 and omicron/BA.1 at visits 3, 4 and 5 in the A) short (circle) and B) extended (triangle) booster groups for SARS-CoV-2 naïve individuals and C) short (grey circle) and D) extended (grey 460 461 triangle) booster groups previously infected individuals. Difference between GMT at visits 3, 4 and 5 were determined using Mann-Whitney unpaired t-test. D'Agostino and Pearson tests 462 463 were performed to determine normality. Based on this result, differences between groups were 464 assessed using either one-way ANOVA (Tukey's multiple comparisons post hoc), Kruskal-465 Wallis test (Dunn's multiple comparisons post hoc) or Friedman test (Dunn's multiple comparisons post hoc). ns P > 0.05, * P \leq 0.05, ** P \leq 0.01, *** P \leq 0.001 and **** P \leq 0.0001. 466 467 Avidity index for IgG binding to Spike was measured at E) visit 3, F) visit 4 and G) visit 5 and 468 compared across groups. Avidity index was calculated by comparing the area under the curve 469 (AUC) with/without an 8M Urea washing step. D'Agostino and Pearson tests were performed 470 to determine normality. Based on this result, differences between groups were assessed using 471 a Kruskal-Wallis test with Dunn's multiple comparisons post hoc. H) Correlations between 472 avidity index and ID₅₀ against VOCs following 2-doses of BNT162b2 vaccine. I) Correlation 473 between avidity index and % Spike-reactive memory B cells. (Spearman's correlation, r, a 474 linear regression was used to calculate the goodness of fit, r^2).



Figure 6: Neutralization against omicron sub-lineages following 3 vaccine doses 476 477 and/or BA.1/BA.2 breakthrough infection. Neutralization breadth and potency was 478 measured against D614G, BA.1, BA.2 and BA.4/BA.5. Analysis of sera collected A) 3-weeks post 3rd BNT162b2 vaccine dose (visit 5), B) 6-months post 3rd vaccine (visit 6) and C) 479 480 following breakthrough infection (visit 7) (presumed to be BA.1 or BA.2). D) Comparison of titres 3-weeks (visit 5) and 6-months post 3rd boost (visit 6). E) Comparison of titres 3-weeks 481 post 3rd boost (visit 5) and following BTI (visit 7). Samples from a single individual are joined. 482 Short and long booster groups shown with circle and triangle symbols, respectively. 483 Individuals infected with SARS-CoV-2 prior to vaccination are shaded grey. Based on this 484 result, multiple Mann-Whitney tests or unpaired t tests using a two-stage linear step-up 485 486 procedure of Benjamini, Krieger and Yekutieli were employed to determine significance between groups. ns P > 0.05, * P \leq 0.05, ** P \leq 0.01, *** P \leq 0.001 and **** P \leq 0.0001. 487



Visit

Visit

489 Acknowledgements

We thank Philip Brouwer, Marit van Gils and Rogier Sanders for the Spike protein construct,
Leo James and Jakub Luptak for the N protein, Wendy Barclay for providing the B.1.617.2,
BA.1, BA.2 and BA.4/BA.5 Spike plasmids and James Voss and Deli Huang for providing the
Hela-ACE2 cells.

- 494
- 495 Funding

This work was funded by; Huo Family Foundation Award to MHM and KJD, MRC Genotype-496 497 to-Phenotype UK National Virology Consortium ([MR/W005611/1] to MHM and KJD), 498 Fondation Dormeur, Vaduz for funding equipment to KJD, Wellcome Trust Investigator Award 499 [222433/Z/21/Z] to MHM, and Wellcome Trust Multi-User Equipment Grant [208354/Z/17/Z] 500 to MHM. and KJD. CG was supported by the MRC-KCL Doctoral Training Partnership in 501 Biomedical Sciences [MR/N013700/1]. DC was supported by a BBSRC CASE in partnership 502 with GlaxoSmithKline [BB/V509632/1]. This work and the Infectious Diseases Biobank (CM) 503 were supported by the Department of Health via a National Institute for Health Research 504 comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation 505 Trust in partnership with King's College London and King's College Hospital NHS Foundation 506 Trust. This study is part of the EDCTP2 programme supported by the European Union (grant 507 number RIA2020EF-3008 COVAB) (KJD, JF, MHM). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This project is supported 508 by a joint initiative between the Botnar Research Centre for Child Health and the European & 509 510 Developing Countries Clinical Trials Partnership (KJD and JF).

511

512 **References**

Lechmere T, Snell LB, Graham C, Seow J, Shalim ZA, Charalampous T, et al. Broad
 Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection
 with Delta in COVID-19-Vaccinated Individuals. mBio. 2022:e0379821. Epub 2022/03/18. doi:
 10.1128/mbio.03798-21. PubMed PMID: 35297676.

517 2. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable 518 neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect

519 Dis. 2022. Epub 2022/04/16. doi: 10.1016/S1473-3099(22)00224-9. PubMed PMID: 520 35427493; PubMed Central PMCID: PMCPMC9005119 grant numbers 01KI2006D, 521 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (grant 522 numbers 14-76103-184, MWK HZI COVID-19), and the German Research Foundation (DFG; grant numbers PO 716/11-1, PO 716/14-1). MSW received unrestricted funding from 523 524 Sartorius, Lung research. H-MJ received funding from BMBF (grant numbers 01KI2043, 525 NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts, 526 and DFG through the research training groups RTG1660 and TRR130, the Bayerische 527 Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges 528 funding from the German Center for Infection Research (grant number 80018019238) and a 529 European Regional Development Fund (Defeat Corona, grant number ZW7-8515131, 530 together with AD-J). All other authors declare no competing interests.

531 3. Doria-Rose NA. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape 532 from Neutralizing Antibodies. medRxiv. 2021. doi: 10.1101/2021.12.15.21267805.

533 4. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA 534 booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 535 Omicron variant. Nat Med. 2022;28(3):477-80. Epub 2022/01/21. doi: 10.1038/s41591-021-536 01676-0. PubMed PMID: 35046572; PubMed Central PMCID: PMCPMC8767537.

537 5. Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet. 2022. Epub 2022/01/23. doi: 538 539 10.1016/S0140-6736(22)00092-7. PubMed PMID: 35065005; PubMed Central PMCID: 540 PMCPMC8769665.

541 UK DoHaSC. Optimising the COVID-19 vaccination programme for maximum short-6. 542 term impact. 2021.

543 7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. 544 Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021;385(24):e85. Epub 545 2021/10/28. doi: 10.1056/NEJMoa2114228. PubMed PMID: 34706170; PubMed Central 546 PMCID: PMCPMC8609604.

547 Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al. Efficient 8. 548 recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 549 2022. Epub 2022/05/07. doi: 10.1016/j.cell.2022.04.009. PubMed PMID: 35523182; PubMed 550 Central PMCID: PMCPMC8989683.

551 Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et 9. 552 al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J 553 Med. 2022;386(19):1804-16. Epub 2022/03/10. doi: 10.1056/NEJMoa2200797. PubMed 554 PMID: 35263534; PubMed Central PMCID: PMCPMC8929389.

555 10. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 556 557 2022;386(16):1532-46. Epub 2022/03/07. doi: 10.1056/NEJMoa2119451. PubMed PMID: 558 35249272; PubMed Central PMCID: PMCPMC8908811.

559 Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association 11. 560 Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-561 CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-51. Epub 2022/01/22. doi: 562 10.1001/jama.2022.0470. PubMed PMID: 35060999; PubMed Central PMCID: 563 PMCPMC8848203.

564 Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct 12. 565 antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals

566 following mRNA vaccination. Sci Immunol. 2021;6(58). Epub 2021/04/17. doi: 567 10.1126/sciimmunol.abi6950. PubMed PMID: 33858945; PubMed Central PMCID: 568 PMCPMC8158969.

569 13. Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, et al. Antibody 570 response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 571 2021;397(10279):1057-8. Epub 2021/03/01. doi: 10.1016/S0140-6736(21)00501-8. PubMed 572 PMID: 33640038; PubMed Central PMCID: PMCPMC7972310.

573 Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA 14. 574 vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021. Epub 2021/03/27. doi: 10.1126/science.abg9175. PubMed PMID: 33766944; 575 576 PubMed Central PMCID: PMCPMC8139425.

577 Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-15. 578 CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 579 2021. Epub 2021/05/02. doi: 10.1126/science.abh1282. PubMed PMID: 33931567; PubMed 580 Central PMCID: PMCPMC8168614.

Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. 581 16. 582 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers 583 Previously Infected With SARS-CoV-2. JAMA. 2021;325(14):1467-9. Epub 2021/03/02. doi: 584 10.1001/jama.2021.3341. PubMed PMID: 33646292; PubMed Central PMCID: 585 PMCPMC7922233.

586 17. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal 587 observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-607. Epub 2020/10/28. doi: 588 589 10.1038/s41564-020-00813-8. PubMed PMID: 33106674.

590 18. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, 591 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;183(6):1735. Epub 592 2020/12/12. doi: 10.1016/j.cell.2020.11.032. PubMed PMID: 33306958.

593 19. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA 594 Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to 595 Variants of Concern. bioRxiv. 2021. Epub 2021/09/01. doi: 10.1101/2021.08.23.457229. 596 PubMed PMID: 34462751; PubMed Central PMCID: PMCPMC8404899.

597 Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody 20. 598 responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by 599 breakthrough infection. Sci Transl Med. 2022;14(637):eabn8057. Epub 2022/02/16. doi: 600 10.1126/scitranslmed.abn8057. PubMed PMID: 35166573; PubMed Central PMCID: 601 PMCPMC8939766.

602 21. Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, et al. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 603 604 2020;53(6):1272-80 e5. Epub 2020/11/27. doi: 10.1016/j.immuni.2020.10.023. PubMed PMID: 33242394; PubMed Central PMCID: PMCPMC7687367 COVA1-16 and other antibodies 605 606 first disclosed by Brouwer et al. (2020) has been filed by Amsterdam UMC under application 607 number 2020-039EP-PR. I.A.W. is a member of the Immunity Editorial Board.

608 Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer 22. 609 Biother Radiopharm. 2009;24(2):155-61. Epub 2009/05/05. doi: 10.1089/cbr.2009.0627. 610 PubMed PMID: 19409036; PubMed Central PMCID: PMCPMC2902227.

611 23. Tauzin A, Gong SY, Beaudoin-Bussieres G, Vezina D, Gasser R, Nault L, et al. Strong 612 humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination

613 with a 16-week interval between doses. Cell Host Microbe. 2022;30(1):97-109 e5. Epub 614 2021/12/27. doi: 10.1016/j.chom.2021.12.004. PubMed PMID: 34953513; PubMed Central 615 PMCID: PMCPMC8639412.

616 Young C, Brink R. The unique biology of germinal center B cells. Immunity. 24. 617 2021;54(8):1652-64. Epub 2021/08/12. doi: 10.1016/j.immuni.2021.07.015. PubMed PMID: 34380063. 618

619 Bjorkman C, Naslund K, Stenlund S, Maley SW, Buxton D, Uggla A. An IgG avidity ELISA 25. 620 to discriminate between recent and chronic Neospora caninum infection. J Vet Diagn Invest. 621 1999;11(1):41-4. Epub 1999/01/30. doi: 10.1177/104063879901100106. PubMed PMID: 9925210. 622

623 26. Tegally H. Continued Emergence and Evolution of Omicron in South Africa: New BA.4 624 and BA.5 lineages. medRxiv. 2022. doi: 10.1101/2022.05.01.22274406.

625 27. Briefing T. 2022.

626 28. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity 627 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 628 2021;184(23):5699-714 e11. Epub 2021/11/05. doi: 10.1016/j.cell.2021.10.011. PubMed 629 PMID: 34735795; PubMed Central PMCID: PMCPMC8519781.

630 Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G, et al. Extended 29. 631 interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022;7(1):14. Epub 2022/01/29. doi: 10.1038/s41541-022-00432-w. PubMed PMID: 632 633 35087066; PubMed Central PMCID: PMCPMC8795435.

634 30. Belik M, Jalkanen P, Lundberg R, Reinholm A, Laine L, Vaisanen E, et al. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing 635 636 antibodies against Delta and Omicron variants. Nat Commun. 2022;13(1):2476. Epub 637 2022/05/06. doi: 10.1038/s41467-022-30162-5. PubMed PMID: 35513437; PubMed Central 638 PMCID: PMCPMC9072399.

639 31. Chatterjee D, Tauzin A, Marchitto L, Gong SY, Boutin M, Bourassa C, et al. SARS-CoV-2 640 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination 641 with a 16-week interval between doses. Cell Rep. 2022;38(9):110429. Epub 2022/02/27. doi: 10.1016/j.celrep.2022.110429. PubMed PMID: 35216664; PubMed Central PMCID: 642 643 PMCPMC8823958.

644 32. Seow J, Graham C, Hallett SR, Lechmere T, Maguire TJA, Huettner I, et al. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-645 646 CoV-2 variants. viral Cell Rep. 2022:110757. Epub 2022/04/28. doi: 647 10.1016/j.celrep.2022.110757. PubMed PMID: 35477023; PubMed Central PMCID: 648 PMCPMC9010245.

649 33. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-44. Epub 2021/01/19. doi: 650 651 10.1038/s41586-021-03207-w. PubMed PMID: 33461210.

Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al. 652 34. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and 653 654 resilience to viral escape mutations. Immunity. 2021;54(8):1853-68 e7. Epub 2021/08/01. doi: 10.1016/j.immuni.2021.07.008. PubMed PMID: 34331873; PubMed Central PMCID: 655 656 PMCPMC8323339.

657 Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, et al. Germinal centre-driven 35. 658 maturation of B cell response to mRNA vaccination. Nature. 2022;604(7904):141-5. Epub 659 2022/02/16. doi: 10.1038/s41586-022-04527-1. PubMed PMID: 35168246.

660 36. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 661 mRNA vaccines induce persistent human germinal centre responses. Nature. 662 2021;596(7870):109-13. Epub 2021/06/29. doi: 10.1038/s41586-021-03738-2. PubMed 663 PMID: 34182569; PubMed Central PMCID: PMCPMC8935394.

Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased 664 37. Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost. Nature. 2022. Epub 665 2022/04/22. doi: 10.1038/s41586-022-04778-y. PubMed PMID: 35447027. 666

667 Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the 38. 668 SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022;386(16):1579-80. Epub 2022/03/17. doi: 10.1056/NEJMc2201849. PubMed PMID: 35294809; PubMed Central 669 670 PMCID: PMCPMC9006770.

Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, et al. Neutralization of SARS-671 39. 672 CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe. 2022. Epub 673 2022/05/09. doi: 10.1016/j.chom.2022.04.014. PubMed PMID: 35526534; PubMed Central 674 PMCID: PMCPMC9035359.

675 40. Willett BJ, Kurshan A, Thakur N, Newman J, Manali M, Tyson G, et al. Distant antigenic 676 properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. bioRxiv. 2022. doi: 677 10.1101/2022.05.25.493397.

678 41. Hachmann NP. Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 679 and BA.4/BA.5. medRxiv. 2022. doi: 10.1101/2022.05.16.22275151.

680 42. Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, et al. Neutralization of the SARS-681 CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. N Engl J Med. 2022. Epub 2022/06/16. doi: 682 10.1056/NEJMc2206725. PubMed PMID: 35704428.

683 43. Khan K, Karim F, Cele S, Reedoy K, San JE, Lustig G, et al. Omicron infection enhances 684 Delta antibody immunity in vaccinated persons. Nature. 2022. Epub 2022/05/07. doi: 685 10.1038/s41586-022-04830-x. PubMed PMID: 35523247.

686 44. Kaku CI, Bergeron AJ, Ahlm C, Normark J, Sakharkar M, Forsell MNE, et al. Recall of 687 pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. Sci Immunol. 2022:eabq3511. Epub 2022/05/14. doi: 10.1126/sciimmunol.abq3511. PubMed 688 689 PMID: 35549299; PubMed Central PMCID: PMCPMC9097882.

690 45. Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson 691 BE, et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions 692 in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022. Epub 693 2022/04/19. doi: 10.1016/j.chom.2022.03.029. PubMed PMID: 35436444; PubMed Central 694 PMCID: PMCPMC8947963.

695 46. Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, et al. Boosting 696 with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell. 2022;185(9):1572-87 e11. Epub 2022/04/23. doi: 10.1016/j.cell.2022.03.037. PubMed 697 PMID: 35452622; PubMed Central PMCID: PMCPMC8958157. 698

699 47. Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, et al. Potent cross-700 reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022;185(12):2116-31 701 e18. Epub 2022/06/07. doi: 10.1016/j.cell.2022.05.014. PubMed PMID: 35662412.

702 Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al. 48. 703 Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 704 2022. Epub 2022/07/01. doi: 10.1016/j.cell.2022.06.005. PubMed PMID: 35772405.

Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz Sandoval D, et al. Immune 705 49. 706 boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 707 2022:eabq1841. Epub 2022/06/15. doi: 10.1126/science.abq1841. PubMed PMID: 35699621. 708 50. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, et al. Two-709 dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: 710 test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis. 2022. 711 Epub 2022/04/20. doi: 10.1093/cid/ciac290. PubMed PMID: 35438175; PubMed Central 712 PMCID: PMCPMC9047203.

713 Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-51. dose administration and the influence of the timing of the booster dose on immunogenicity 714 and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised 715 716 2021;397(10277):881-91. 2021/02/23. trials. Lancet. Epub doi: 10.1016/S0140-6736(21)00432-3. PubMed PMID: 33617777; PubMed Central PMCID: PMCPMC7894131. 717

718 52. Hall VG, Ferreira VH, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K, et al. Delayed-719 interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces 720 robust T cell responses. Nat Immunol. 2022;23(3):380-5. Epub 2022/02/05. doi: 721 10.1038/s41590-021-01126-6. PubMed PMID: 35115679.

722 Pickering S, Betancor G, Galao RP, Merrick B, Signell AW, Wilson HD, et al. Comparative 53. 723 assessment of multiple COVID-19 serological technologies supports continued evaluation of 724 point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 725 2020;16(9):e1008817. Epub 2020/09/25. doi: 10.1371/journal.ppat.1008817. PubMed PMID: 726 32970782; PubMed Central PMCID: PMCPMC7514033.

727 54. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, et al. Neutralizing 728 antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants 729 of concern. Nat Microbiol. 2021;6(11):1433-42. Epub 2021/10/17. doi: 10.1038/s41564-021-730 00974-0. PubMed PMID: 34654917; PubMed Central PMCID: PMCPMC8556155.

731 55. Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-732 CoV spike expressing viral pseudotypes. MethodsX. 2015;2:379-84. Epub 2015/11/21. doi: 733 10.1016/j.mex.2015.09.003. PubMed PMID: 26587388; PubMed Central PMCID: 734 PMCPMC4625112.

Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenco J, Penman BS, et al. 735 56. 736 Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 2020;25(42). Epub 737 738 2020/10/24. doi: 10.2807/1560-7917.ES.2020.25.42.2000685. PubMed PMID: 33094713; 739 PubMed Central PMCID: PMCPMC7651873.

740

741